{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:19:56Z","timestamp":1787030396681,"version":"build-2736575974"},"reference-count":98,"publisher":"China Science Publishing & Media Ltd.","issue":"11","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2024,11,1]]},"DOI":"10.3724\/abbs.2024149","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T21:20:41Z","timestamp":1724707241000},"page":"1573-1583","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications"],"prefix":"10.3724","volume":"56","author":[{"given":"Yangyue","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"Devarbhavi H","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol, 2023, 79: 516-537.","journal-title":"J Hepatol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Younossi Z","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15: 11-20.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"Zhou J","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG. Epidemiological features of NAFLD from 1999 to 2018 in China. J Hepatol, 2020, 71: 1851-1864.","journal-title":"J Hepatol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. J Hepatol, 2018, 67: 123-133.","journal-title":"J Hepatol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"Estes C","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol, 2018, 69: 896-904.","journal-title":"J Hepatol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","volume":"23","author":"Guo X","year":"2022","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci, 2022, 23:","journal-title":"Int J Mol Sci"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41575-018-0094-6","volume":"16","author":"Younes R","year":"2019","unstructured":"Younes R, Bugianesi E. A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. Nat Rev Gastroenterol Hepatol, 2019, 16: 80-82.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ceb.2006.08.005","volume":"18","author":"Luo BH","year":"2006","unstructured":"Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol, 2006, 18: 579-586.","journal-title":"Curr Opin Cell Biol"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"113300","DOI":"10.1016\/j.biopha.2022.113300","volume":"153","author":"Yao Y","year":"2022","unstructured":"Yao Y, Liu H, Yuan L, Du X, Yang Y, Zhou K, Wu X. Integrins are double-edged swords in pulmonary infectious diseases. Biomed Pharmacother, 2022, 153:","journal-title":"Biomed Pharmacother"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3748\/wjg.v19.i8.1158","volume":"19","author":"Basaranoglu M","year":"2013","unstructured":"Basaranoglu M. From fatty liver to fibrosis: a tale of \u201csecond hit\u201d. World J Gastroenterol, 2013, 19:","journal-title":"World J Gastroenterol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"Buzzetti E","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65: 1038-1048.","journal-title":"Metabolism"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/hep.26986","volume":"59","author":"Wong RJ","year":"2014","unstructured":"Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. J Hepatol, 2014, 59: 2188-2195.","journal-title":"J Hepatol"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000002459","volume":"136","author":"Gao Q","year":"2023","unstructured":"Gao Q, Sun Z, Fang D. Integrins in human hepatocellular carcinoma tumorigenesis and therapy. Chin Med J, 2023, 136: 253-268.","journal-title":"Chin Med J"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med, 2023, 29: 562-573.","journal-title":"Nat Med"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0092-8674(87)90233-9","volume":"48","author":"Hynes RO","year":"1987","unstructured":"Hynes RO. Integrins: a family of cell surface receptors. Cell, 1987, 48: 549-554.","journal-title":"Cell"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.matbio.2004.08.001","volume":"23","author":"Hynes RO","year":"2004","unstructured":"Hynes RO. The emergence of integrins: a personal and historical perspective. Matrix Biol, 2004, 23: 333-340.","journal-title":"Matrix Biol"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"Pang X","year":"2023","unstructured":"Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y. Targeting integrin pathways: mechanisms and advances in therapy. Sig Transduct Target Ther, 2023, 8:","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4161\/cam.18702","volume":"6","author":"Zhang K","year":"2012","unstructured":"Zhang K, Chen JF. The regulation of integrin function by divalent cations. Cell Adh Migr, 2012, 6: 20-29.","journal-title":"Cell Adh Migr"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","volume":"89","author":"Mezu-Ndubuisi OJ","year":"2021","unstructured":"Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr Res, 2021, 89: 1619-1626.","journal-title":"Pediatr Res"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1126\/science.2821619","volume":"238","author":"Ruoslahti E","year":"1987","unstructured":"Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238: 491-497.","journal-title":"Science"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1242\/jcs.03098","volume":"119","author":"Humphries JD","year":"2006","unstructured":"Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci, 2006, 119: 3901-3903.","journal-title":"J Cell Sci"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/IJN.S101366","volume":"11","author":"Wang DB","year":"2016","unstructured":"Wang DB, Zhang C, Liu H, Cui Y, Li X, Zhang Z, Zhang Y. Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin alphavbeta(3) for staging liver fibrosis in rat model. Int J Nanomedicine, 2016, 11: 1097-1108.","journal-title":"Int J Nanomedicine"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1146\/annurev.immunol.25.022106.141618","volume":"25","author":"Luo BH","year":"2007","unstructured":"Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol, 2007, 25: 619-647.","journal-title":"Annu Rev Immunol"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood.2019003336","volume":"135","author":"Nolte MA","year":"2020","unstructured":"Nolte MA, Margadant C. Activation and suppression of hematopoietic integrins in hemostasis and immunity. Blood, 2020, 135: 7-16.","journal-title":"Blood"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1538-7836.2011.04355.x","volume":"9","author":"Ye F","year":"2011","unstructured":"Ye F, Kim C, Ginsberg MH. Molecular mechanism of inside-out integrin regulation. J Thromb Haemost, 2011, 9: 20-25.","journal-title":"J Thromb Haemost"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","volume":"21","author":"Slack RJ","year":"2022","unstructured":"Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov, 2022, 21: 60-78.","journal-title":"Nat Rev Drug Discov"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nri1222","volume":"3","author":"von Andrian UH","year":"2003","unstructured":"von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol, 2003, 3: 867-878.","journal-title":"Nat Rev Immunol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41598-018-19454-3","volume":"8","author":"Chae YK","year":"2018","unstructured":"Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. Sci Rep, 2018, 8:","journal-title":"Sci Rep"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"Ley K","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol, 2007, 7: 678-689.","journal-title":"Nat Rev Immunol"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nri2986","volume":"11","author":"Hogg N","year":"2011","unstructured":"Hogg N, Patzak I, Willenbrock F. The insider\u2019s guide to leukocyte integrin signalling and function. Nat Rev Immunol, 2011, 11: 416-426.","journal-title":"Nat Rev Immunol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/02656736.2019.1647357","volume":"36","author":"Lin CD","year":"2019","unstructured":"Lin CD, Chen JF. Regulation of immune cell trafficking by febrile temperatures. Int J Hyperthermia, 2019, 36: 17-21.","journal-title":"Int J Hyperthermia"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2005.06.007","volume":"23","author":"Bonder CS","year":"2005","unstructured":"Bonder CS, Norman MU, Swain MG, Zbytnuik LD, Yamanouchi J, Santamaria P, Ajuebor M. Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. Immunity, 2005, 23: 153-163.","journal-title":"Immunity"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.4049\/jimmunol.172.9.5222","volume":"172","author":"John B","year":"2004","unstructured":"John B, Crispe IN. Passive and active mechanisms trap activated CD8+ T cells in the liver. J Immunol, 2004, 172: 5222-5229.","journal-title":"J Immunol"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"eaba2351","DOI":"10.1126\/sciimmunol.aba2351","volume":"5","author":"Ficht X","year":"2020","unstructured":"Ficht X, Iannacone M. Immune surveillance of the liver by T cells. Sci Immunol, 2020, 5:","journal-title":"Sci Immunol"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","volume":"161","author":"Guidotti LG","year":"2015","unstructured":"Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, Fiocchi A. Immunosurveillance of the liver by intravascular effector CD8+ T Cells. Cell, 2015, 161: 486-500.","journal-title":"Cell"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6793-7-10","volume":"7","author":"Ando T","year":"2007","unstructured":"Ando T, Langley RR, Wang Y, Jordan PA, Minagar A, Alexander JS, Jennings MH. Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion in vitro. BMC Physiol, 2007, 7:","journal-title":"BMC Physiol"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2011.12.035","volume":"57","author":"Crispe IN","year":"2012","unstructured":"Crispe IN. Migration of lymphocytes into hepatic sinusoids. J Hepatol, 2012, 57: 218-220.","journal-title":"J Hepatol"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.4049\/jimmunol.1002961","volume":"186","author":"Shetty S","year":"2011","unstructured":"Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, Hubscher SG. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol, 2011, 186: 4147-4155.","journal-title":"J Immunol"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2020.05.047","volume":"73","author":"Rai RP","year":"2020","unstructured":"Rai RP, Liu Y, Iyer SS, Liu S, Gupta B, Desai C, Kumar P. Blocking integrin \u03b14\u03b27-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. J Hepatol, 2020, 73: 1013-1022.","journal-title":"J Hepatol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/hep.23168","volume":"50","author":"Zhang M","year":"2009","unstructured":"Zhang M, Han Y, Han C, Xu S, Bao Y, Chen Z, Gu Y. The \u03b22 integrin CD11b attenuates polyinosinic: polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions. J Hepatol, 2009, 50: 1606-1616.","journal-title":"J Hepatol"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/liv.15157","volume":"42","author":"Rahman SR","year":"2022","unstructured":"Rahman SR, Roper JA, Grove JI, Aithal GP, Pun KT, Bennett AJ. Integrins as a drug target in liver fibrosis. Liver Int, 2022, 42: 507-521.","journal-title":"Liver Int"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","volume":"24","author":"Fang YL","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d. World J Gastroenterol, 2018, 24: 2974-2983.","journal-title":"World J Gastroenterol"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","volume":"7","author":"Lim JS","year":"2010","unstructured":"Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol, 2010, 7: 251-264.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/s0016-5085(98)70599-2","volume":"114","author":"Day CP","year":"1998","unstructured":"Day CP, James OFW. Steatohepatitis: a tale of two \u201chits\u201d?. Gastroenterology, 1998, 114: 842-845.","journal-title":"Gastroenterology"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1074\/jbc.M114.615716","volume":"290","author":"Williams AS","year":"2015","unstructured":"Williams AS, Kang L, Zheng J, Grueter C, Bracy DP, James FD, Pozzi A. Integrin \u03b11-null mice exhibit improved fatty liver when fed a high fat diet despite severe hepatic insulin resistance. J Biol Chem, 2015, 290: 6546-6557.","journal-title":"J Biol Chem"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.3390\/nu14183871","volume":"14","author":"Yao Q","year":"2022","unstructured":"Yao Q, Liu J, Cui Q, Jiang T, Xie X, Du X, Zhao Z. CCN1\/integrin \u03b15\u03b21 instigates free fatty acid-induced hepatocyte lipid accumulation and pyroptosis through NLRP3 inflammasome activation. Nutrients, 2022, 14:","journal-title":"Nutrients"},{"key":"CITATION47","doi-asserted-by":"crossref","unstructured":"Trefts E, Ghoshal K, DO AV, Guerin A, Guan C, Bracy D, Lantier L, et al. 294-OR: hepatic integrin \u03b21 subunit is required for liver insulin resistance but not fatty liver in diet-induced obese mice. Diabetes 2023, 72.","DOI":"10.2337\/db23-294-OR"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"Tilg H","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. J Hepatol, 2021, 73: 833-842.","journal-title":"J Hepatol"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"Schuster S","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol, 2018, 15: 349-364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fimmu.2019.00893","volume":"10","author":"Weston CJ","year":"2019","unstructured":"Weston CJ, Zimmermann HW, Adams DH. The role of myeloid-derived cells in the progression of liver disease. Front Immunol, 2019, 10:","journal-title":"Front Immunol"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"34466","DOI":"10.1038\/srep34466","volume":"6","author":"Nakashima H","year":"2016","unstructured":"Nakashima H, Nakashima M, Kinoshita M, Ikarashi M, Miyazaki H, Hanaka H, Imaki J. Activation and increase of radio-sensitive CD11b+ recruited Kupffer cells\/macrophages in diet-induced steatohepatitis in FGF5 deficient mice. Sci Rep, 2016, 6:","journal-title":"Sci Rep"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"e92902","DOI":"10.1172\/jci.insight.92902","volume":"2","author":"Itoh M","year":"2017","unstructured":"Itoh M, Suganami T, Kato H, Kanai S, Shirakawa I, Sakai T, Goto T. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight, 2017, 2:","journal-title":"JCI Insight"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","volume":"27","author":"Deczkowska A","year":"2021","unstructured":"Deczkowska A, David E, Ramadori P, Pfister D, Safran M, Li B, Giladi A. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med, 2021, 27: 1043-1054.","journal-title":"Nat Med"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jhep.2017.01.008","volume":"66","author":"Heier EC","year":"2017","unstructured":"Heier EC, Meier A, Julich-Haertel H, Djudjaj S, Rau M, Tschernig T, Geier A. Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis. J Hepatol, 2017, 66: 1241-1250.","journal-title":"J Hepatol"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"Sutti S","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol, 2020, 17: 81-92.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.32193","volume":"75","author":"Graham JJ","year":"2022","unstructured":"Graham JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, Si T, Huang Z, Huang X. Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. J Hepatol, 2022, 75: 518-530.","journal-title":"J Hepatol"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-018-0849-9","volume":"566","author":"He S","year":"2019","unstructured":"He S, Kahles F, Rattik S, Nairz M, McAlpine CS, Anzai A, Selgrade D. Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease. Nature, 2019, 566: 115-119.","journal-title":"Nature"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cmet.2015.03.001","volume":"21","author":"Luck H","year":"2015","unstructured":"Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo XS, Lei H. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab, 2015, 21: 527-542.","journal-title":"Cell Metab"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2017.02.016","volume":"152","author":"Hong CP","year":"2017","unstructured":"Hong CP, Park A, Yang BG, Yun CH, Kwak MJ, Lee GW, Kim JH. Gut-specific delivery of T-helper 17 cells reduces obesity and insulin resistance in mice. Gastroenterology, 2017, 152: 1998-2010.","journal-title":"Gastroenterology"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.etap.2016.01.021","volume":"42","author":"Liu J","year":"2016","unstructured":"Liu J, Quan J, Feng J, Zhang Q, Xu Y, Liu J, Huang W. High glucose regulates LN expression in human liver sinusoidal endothelial cells through ROS\/integrin \u03b1v\u03b23 pathway. Environ Toxicol Pharmacol, 2016, 42: 231-236.","journal-title":"Environ Toxicol Pharmacol"},{"key":"CITATION61","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"Henderson NC","year":"2013","unstructured":"Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med, 2013, 19: 1617-1624.","journal-title":"Nat Med"},{"key":"CITATION62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","volume":"48","author":"Popov Y","year":"2008","unstructured":"Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A. Integrin \u03b1v\u03b26 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol, 2008, 48: 453-464.","journal-title":"J Hepatol"},{"key":"CITATION63","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13550-020-00704-3","volume":"10","author":"Hiroyama S","year":"2020","unstructured":"Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, Fujisawa K. Quantitative evaluation of hepatic integrin \u03b1v\u03b23 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res, 2020, 10:","journal-title":"EJNMMI Res"},{"key":"CITATION64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13550-018-0394-4","volume":"8","author":"Rokugawa T","year":"2018","unstructured":"Rokugawa T, Konishi H, Ito M, Iimori H, Nagai R, Shimosegawa E, Hatazawa J. Evaluation of hepatic integrin \u03b1v\u03b23 expression in non-alcoholic steatohepatitis (NASH) model mouse by 18F-FPP-RGD2 PET. EJNMMI Res, 2018, 8:","journal-title":"EJNMMI Res"},{"key":"CITATION65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2019.04.022","volume":"303","author":"Li Y","year":"2019","unstructured":"Li Y, Pu S, Liu Q, Li R, Zhang J, Wu T, Chen L. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Control Release, 2019, 303: 77-90.","journal-title":"J Control Release"},{"key":"CITATION66","doi-asserted-by":"publisher","first-page":"G425","DOI":"10.1152\/ajpgi.00050.2011","volume":"301","author":"Patsenker E","year":"2011","unstructured":"Patsenker E, Stickel F. Role of integrins in fibrosing liver diseases. Am J Physiol Gastrointestinal Liver Physiol, 2011, 301: G425-G434.","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"key":"CITATION67","doi-asserted-by":"publisher","first-page":"12794","DOI":"10.3390\/ijms222312794","volume":"22","author":"Yokosaki Y","year":"2021","unstructured":"Yokosaki Y, Nishimichi N. New therapeutic targets for hepatic fibrosis in the integrin family, \u03b18\u03b21 and \u03b111\u03b21, induced specifically on activated stellate cells. Int J Mol Sci, 2021, 22:","journal-title":"Int J Mol Sci"},{"key":"CITATION68","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/path.5618","volume":"253","author":"Nishimichi N","year":"2021","unstructured":"Nishimichi N, Tsujino K, Kanno K, Sentani K, Kobayashi T, Chayama K, Sheppard D. Induced hepatic stellate cell integrin, \u03b18\u03b21, enhances cellular contractility and TGF\u03b2 activity in liver fibrosis. J Pathol, 2021, 253: 366-373.","journal-title":"J Pathol"},{"key":"CITATION69","doi-asserted-by":"publisher","first-page":"936196","DOI":"10.3389\/fimmu.2022.936196","volume":"13","author":"Du W","year":"2022","unstructured":"Du W, Wang L. The crosstalk between liver sinusoidal endothelial cells and hepatic microenvironment in NASH related liver fibrosis. Front Immunol, 2022, 13:","journal-title":"Front Immunol"},{"key":"CITATION70","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jhep.2019.07.019","volume":"71","author":"Guo Q","year":"2019","unstructured":"Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, Kabashima A. Integrin \u03b21-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol, 2019, 71: 1193-1205.","journal-title":"J Hepatol"},{"key":"CITATION71","doi-asserted-by":"crossref","unstructured":"Altrock E, Sens C, Kawelke N, Nakchbandi IA. Loss of Integrin-\u03b21 in hepatocytes induces liver fibrosis. Z Gastroenterol 2015, 53: A1_34.","DOI":"10.1055\/s-0034-1397075"},{"key":"CITATION72","doi-asserted-by":"publisher","first-page":"95586","DOI":"10.18632\/oncotarget.21525","volume":"8","author":"Zheng X","year":"2017","unstructured":"Zheng X, Liu W, Xiang J, Liu P, Ke M, Wang B, Wu R. Collagen I promotes hepatocellular carcinoma cell proliferation by regulating integrin \u03b21\/FAK signaling pathway in nonalcoholic fatty liver. Oncotarget, 2017, 8: 95586-95595.","journal-title":"Oncotarget"},{"key":"CITATION73","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.7150\/ijbs.72367","volume":"18","author":"Peng Z","year":"2022","unstructured":"Peng Z, Hao M, Tong H, Yang H, Huang B, Zhang Z, Luo KQ. The interactions between integrin \u03b15 \u03b21 of liver cancer cells and fibronectin of fibroblasts promote tumor growth and angiogenesis. Int J Biol Sci, 2022, 18: 5019-5037.","journal-title":"Int J Biol Sci"},{"key":"CITATION74","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14728222.2011.555402","volume":"15","author":"Wu Y","year":"2011","unstructured":"Wu Y, Qiao X, Qiao S, Yu L. Targeting integrins in hepatocellular carcinoma. Expert Opin Ther Targets, 2011, 15: 421-437.","journal-title":"Expert Opin Ther Targets"},{"key":"CITATION75","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2016.03.023","volume":"376","author":"Leng C","year":"2016","unstructured":"Leng C, Zhang Z, Chen W, Luo H, Song J, Dong W, Zhu X. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK\u2013AKT pathway. Cancer Lett, 2016, 376: 188-196.","journal-title":"Cancer Lett"},{"key":"CITATION76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-020-01307-7","volume":"20","author":"Li J","year":"2020","unstructured":"Li J, Hao N, Han J, Zhang M, Li X, Yang N. ZKSCAN3 drives tumor metastasis via integrin \u03b24\/FAK\/AKT mediated epithelial\u2013mesenchymal transition in hepatocellular carcinoma. Cancer Cell Int, 2020, 20:","journal-title":"Cancer Cell Int"},{"key":"CITATION77","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13046-019-1455-x","volume":"38","author":"Sun F","year":"2019","unstructured":"Sun F, Wang J, Sun Q, Li F, Gao H, Xu L, Zhang J. Interleukin-8 promotes integrin \u03b23 upregulation and cell invasion through PI3K\/Akt pathway in hepatocellular carcinoma. J Exp Clin Cancer Res, 2019, 38:","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION78","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.3892\/mmr.2014.3140","volume":"11","author":"Xu ZZ","year":"2015","unstructured":"Xu ZZ, Xiu P, Lv JW, Wang FH, Dong XF, Liu F, Li T. Integrin \u03b1v\u03b23 is required for cathepsin B-induced hepatocellular carcinoma progression. Mol Med Rep, 2015, 11: 3499-3504.","journal-title":"Mol Med Rep"},{"key":"CITATION79","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-08-1028","volume":"15","author":"Wu Y","year":"2009","unstructured":"Wu Y, Zuo J, Ji G, Saiyin H, Liu X, Yin F, Cao N. Proapoptotic function of integrin \u03b23 in human hepatocellular carcinoma cells. Clin Cancer Res, 2009, 15: 60-69.","journal-title":"Clin Cancer Res"},{"key":"CITATION80","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2559.2004.01919.x","volume":"45","author":"Sipos B","year":"2004","unstructured":"Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman SL. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology, 2004, 45: 226-236.","journal-title":"Histopathology"},{"key":"CITATION81","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2009.12.006","volume":"52","author":"Patsenker E","year":"2010","unstructured":"Patsenker E, Wilkens L, Banz V, \u00d6sterreicher CH, Weimann R, Eisele S, Keogh A. The \u03b1v\u03b26 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol, 2010, 52: 362-369.","journal-title":"J Hepatol"},{"key":"CITATION82","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12149-017-1173-4","volume":"31","author":"Zheng J","year":"2017","unstructured":"Zheng J, Miao W, Huang C, Lin H. Evaluation of 99mTc-3PRGD2 integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with 18F-FDG metabolic imaging. Ann Nucl Med, 2017, 31: 486-494.","journal-title":"Ann Nucl Med"},{"key":"CITATION83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/JHC.S312921","volume":"8","author":"Lin BQ","year":"2021","unstructured":"Lin BQ, Zhang WB, Zhao J, Zhou XH, Li YJ, Deng J, Zhao Q. An optimized integrin \u03b16-targeted magnetic resonance probe for molecular imaging of hepatocellular carcinoma in mice. J Hepatocell Carcinoma, 2021, 8: 645-656.","journal-title":"J Hepatocell Carcinoma"},{"key":"CITATION84","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13139-023-00791-9","volume":"57","author":"Hiroyama S","year":"2023","unstructured":"Hiroyama S, Matsunaga K, Ito M, Iimori H, Morita I, Nakamura J, Shimosegawa E. Evaluation of an integrin \u03b1v\u03b23 radiotracer, [18F]F-FPP-RGD2, for monitoring pharmacological effects of integrin alpha(v) siRNA in the NASH liver. Nucl Med Mol Imag, 2023, 57: 172-179.","journal-title":"Nucl Med Mol Imag"},{"key":"CITATION85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhep.2020.02.018","volume":"73","author":"Shao T","year":"2020","unstructured":"Shao T, Chen Z, Belov V, Wang X, Rwema SH, Kumar V, Fu H. [18F]-Alfatide PET imaging of integrin \u03b1v\u03b23 for the non-invasive quantification of liver fibrosis. J Hepatol, 2020, 73: 161-169.","journal-title":"J Hepatol"},{"key":"CITATION86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CEG.S293272","volume":"14","author":"Gubatan J","year":"2021","unstructured":"Gubatan J, Keyashian K, Rubin SJ, Wang J, Buckman C, Sinha S. Anti-Integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol, 2021, 14: 333-342.","journal-title":"Clin Exp Gastroenterol"},{"key":"CITATION87","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3389\/fimmu.2019.00979","volume":"10","author":"Yossipof TE","year":"2019","unstructured":"Yossipof TE, Bazak ZR, Kenigsbuch-Sredni D, Caspi RR, Kalechman Y, Sredni B. Tellurium compounds prevent and reverse type-1 diabetes in NOD mice by modulating \u03b14\u03b27 integrin activity, IL-1\u03b2, and T regulatory cells. Front Immunol, 2019, 10:","journal-title":"Front Immunol"},{"key":"CITATION88","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/molecules24081537","volume":"24","author":"Morshed A","year":"2019","unstructured":"Morshed A, Abbas AB, Hu J, Xu H. Shedding new light on the role of \u03b1\u03bd\u03b23 and \u03b15\u03b21 integrins in rheumatoid arthritis. Molecules, 2019, 24:","journal-title":"Molecules"},{"key":"CITATION89","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/ar3464","volume":"13","author":"Lowin T","year":"2011","unstructured":"Lowin T, Straub RH. Integrins and their ligands in rheumatoid arthritis. Arthritis Res Ther, 2011, 13:","journal-title":"Arthritis Res Ther"},{"key":"CITATION90","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-06-2779","volume":"13","author":"Mullamitha SA","year":"2007","unstructured":"Mullamitha SA, Ton NC, Parker GJM, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res, 2007, 13: 2128-2135.","journal-title":"Clin Cancer Res"},{"key":"CITATION91","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"Besse B","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol, 2013, 24: 90-96.","journal-title":"Ann Oncol"},{"key":"CITATION92","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41598-017-03296-6","volume":"7","author":"Zhou Y","year":"2017","unstructured":"Zhou Y, Gao S, Huang Y, Zheng J, Dong Y, Zhang B, Zhao S. A pilot study of 18F-alfatide PET\/CT imaging for detecting lymph node metastases in patients with non-small cell lung cancer. Sci Rep, 2017, 7:","journal-title":"Sci Rep"},{"key":"CITATION93","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13550-021-00842-2","volume":"11","author":"Steiger K","year":"2021","unstructured":"Steiger K, Quigley NG, Groll T, Richter F, Zierke MA, Beer AJ, Weichert W. There is a world beyond \u03b1v\u03b23-integrin: multimeric ligands for imaging of the integrin subtypes \u03b1v\u03b26, \u03b1v\u03b28, \u03b1v\u03b23, and \u03b15\u03b21 by positron emission tomography. EJNMMI Res, 2021, 11:","journal-title":"EJNMMI Res"},{"key":"CITATION94","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17460441.2020.1819234","volume":"16","author":"Cox D","year":"2021","unstructured":"Cox D. How not to discover a drug\u2014integrins. Expert Opin Drug Discov, 2021, 16: 197-211.","journal-title":"Expert Opin Drug Discov"},{"key":"CITATION95","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","volume":"33","author":"Grant AJ","year":"2001","unstructured":"Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). J Hepatol, 2001, 33: 1065-1072.","journal-title":"J Hepatol"},{"key":"CITATION96","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"Colombel JF","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2032Haens G, Panaccione R. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut, 2017, 66: 839-851.","journal-title":"Gut"},{"key":"CITATION97","doi-asserted-by":"publisher","first-page":"965","DOI":"10.14218\/JCTH.2021.00564","volume":"10","author":"Koullias ES","year":"2022","unstructured":"Koullias ES, Koskinas J. Pharmacotherapy for non-alcoholic fatty liver disease associated with diabetes mellitus type 2. J Clin Transl Hepatol, 2022, 10: 965-971.","journal-title":"J Clin Transl Hepatol"},{"key":"CITATION98","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.tibs.2021.11.003","volume":"47","author":"Gahmberg CG","year":"2022","unstructured":"Gahmberg CG, Gr\u00f6nholm M. How integrin phosphorylations regulate cell adhesion and signaling. Trends Biochem Sci, 2022, 47: 265-278.","journal-title":"Trends Biochem Sci"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/ABBC50B7C537467783C2D63A82A439E2","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2024149","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/ABBC50B7C537467783C2D63A82A439E2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:16:51Z","timestamp":1732771011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2024149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":98,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,14]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2024149","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}